These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 14963986

  • 1. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec 04; 145(49):18-9. PubMed ID: 14963986
    [No Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 04; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. [New options against undertreatment].
    Pfeffer M.
    MMW Fortschr Med; 2003 Dec 04; 145(49):18. PubMed ID: 14963987
    [No Abstract] [Full Text] [Related]

  • 4. Heart attack patients with complications. Treat with valsartan, captopril, or both?
    Nguyen A, Sharma S.
    Can Fam Physician; 2004 Aug 04; 50():1093-5. PubMed ID: 15455807
    [No Abstract] [Full Text] [Related]

  • 5. Valsartan, captopril, or both in myocardial infarction.
    McAnulty JH.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
    [No Abstract] [Full Text] [Related]

  • 6. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 7. Valsartan an alternative to ACE inhibitor in high-risk MI.
    Geriatrics; 2004 Jan 21; 59(1):45. PubMed ID: 14755870
    [No Abstract] [Full Text] [Related]

  • 8. Valsartan, captopril, or both in myocardial infarction.
    Moshenyat R, Kupfer Y, Tessler S.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
    [No Abstract] [Full Text] [Related]

  • 9. Valsartan, captopril, or both in myocardial infarction.
    Jorde UP.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
    [No Abstract] [Full Text] [Related]

  • 10. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
    MMW Fortschr Med; 2003 Oct 23; 145(43):51. PubMed ID: 14664222
    [No Abstract] [Full Text] [Related]

  • 11. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
    Sarzani R, Dessì-Fulgheri P.
    J Hypertens; 2006 Aug 29; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
    [No Abstract] [Full Text] [Related]

  • 13. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators.
    N Engl J Med; 2003 Nov 13; 349(20):1893-906. PubMed ID: 14610160
    [Abstract] [Full Text] [Related]

  • 14. VALIANT trial results support use of valsartan in acute myocardial infarction.
    Cardiovasc J S Afr; 2004 Nov 13; 15(1):45, 47. PubMed ID: 15095754
    [No Abstract] [Full Text] [Related]

  • 15. [AT(1) blocker for post-infarct therapy. VALIANT Study].
    Hasenfuss G.
    Internist (Berl); 2004 Aug 13; 45(8):946-8. PubMed ID: 15252713
    [No Abstract] [Full Text] [Related]

  • 16. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA.
    Circulation; 2004 Sep 21; 110(12):1572-8. PubMed ID: 15364810
    [Abstract] [Full Text] [Related]

  • 17. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.
    Mann DL, Deswal A.
    N Engl J Med; 2003 Nov 13; 349(20):1963-5. PubMed ID: 14610159
    [No Abstract] [Full Text] [Related]

  • 19. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug 13; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 20. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
    Maggioni AP, Fabbri G.
    Expert Opin Pharmacother; 2005 Mar 13; 6(3):507-12. PubMed ID: 15794740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.